Darroudi Mahdieh, Elnaz Nazari Seyedeh, Karimzadeh Maryam, Asgharzadeh Fereshteh, Khalili-Tanha Nima, Asghari Seyyedeh Zahra, Ranjbari Sara, Babaei Fatemeh, Rezayi Majid, Khazaei Majid
Department of Physiology, Faculty of Medicine, Mashhad University of Medical Science, Mashhad, Iran.
Department of Medical Biotechnology and Nanotechnology, School of Science, Mashhad University of Medical Science, Mashhad, Iran.
Front Bioeng Biotechnol. 2023 Jan 25;11:1097631. doi: 10.3389/fbioe.2023.1097631. eCollection 2023.
Cervical cancer is the leading cause of cancer-related death in women, so novel therapeutic approaches are needed to improve the effectiveness of current therapies or extend their activity. In recent decades, graphene analogs, such as Mxene, an emerging class of two-dimensional (2D) graphene analogs, have been drawing considerable attention based on their intrinsic physicochemical properties and performance as potential candidates for tumor therapy, particularly for therapeutic purposes. Here we explored the targeted drug delivery in cervical cancer in model. Mxene-based nanocarriers are not able to be precisely controlled in cancer treatment. To solve this problem, the titanium carbide-magnetic core-shell nanocarrier (TiC-FeO@SiO-FA) is also developed to provide synergetic anticancer with magnetic controlling ability along with pH-responsive drug release. A xenograft model of the cervix was used to investigate the effects of Cisplatin alone, or in combination with TiC@FA and TiC@ FeO@SiO-FA, on tumor growth following histological staining for evaluation of necrosis. A significant tumor-growth suppression effect is shown when the TiC-FeO@SiO-FA nanocarrier is magnetically controlled Cisplatin drug release. It reveals a synergistic therapeutic efficacy used in conjunction with pharmaceuticals ( < .001). According to the study, the TiC@FA@Cisplatin nanocomposite exhibits less tumor growth than the drug alone or TiC@FA@Cisplatin increasing necrosis effect ( < .001). Through this study, Mxene nanosheets are expanded for biomedical applications, not only through the fabrication of biocompatible magnetic Mxene nanocomposite but also through the development of functionalization strategies that enable the magnetic TiC nanocomposite to load high levels of Cisplatin for cervical cancer treatment (242.5%). Hence, TiC-FeO@SiO-FA nanocarriers would be promising candidates to improve cancer treatment efficiency.
宫颈癌是女性癌症相关死亡的主要原因，因此需要新的治疗方法来提高现有疗法的有效性或扩大其作用范围。近几十年来，石墨烯类似物，如新兴的二维（2D）石墨烯类似物Mxene，因其内在的物理化学性质和作为肿瘤治疗潜在候选物的性能，特别是治疗用途，而备受关注。在这里，我们在模型中探索了宫颈癌的靶向药物递送。基于Mxene的纳米载体在癌症治疗中无法得到精确控制。为了解决这个问题，还开发了碳化钛-磁性核壳纳米载体（TiC-FeO@SiO-FA），以提供具有磁控能力和pH响应药物释放的协同抗癌作用。使用宫颈异种移植模型研究顺铂单独使用或与TiC@FA和TiC@FeO@SiO-FA联合使用对肿瘤生长的影响，随后进行组织学染色以评估坏死情况。当TiC-FeO@SiO-FA纳米载体进行磁控顺铂药物释放时，显示出显著的肿瘤生长抑制作用。它揭示了与药物联合使用时具有协同治疗效果（P<0.001）。根据该研究，TiC@FA@顺铂纳米复合材料的肿瘤生长比单独使用药物或TiC@FA时更少，且增加了坏死效果（P<0.001）。通过这项研究，Mxene纳米片不仅通过制备生物相容性磁性Mxene纳米复合材料，还通过开发功能化策略来扩展其生物医学应用，这些策略使磁性TiC纳米复合材料能够负载高水平的顺铂用于宫颈癌治疗（242.5%）。因此，TiC-FeO@SiO-FA纳米载体有望成为提高癌症治疗效率的候选材料。
